UA-107708939-1
Your browser version is outdated. We recommend that you update your browser to the latest version.

News

November 2017MonTa Biosciences attends the BioEurope partnering conference in Berlin from November 4-8. Please book a meeting with us if you wish to discuss partnership or Investment opportunities.

 

October 2017MonTa Biosciences announces completion of license agreements with UC San Diego and Danish Technical University. The immune stimulating TLR7 agonist is licensed from the internationally recognized and leading group in discovery of TLR agonists, headed by Dennis Carson at UC San Diego. The TLR7 agonist is combined with nanoparticels developed at DTU Nanotech and together forms a new strategy for boosting the immune system in a more efficient approach. Read more about the press release in this Medwatch article.

September 2017MonTa Biosciences attends the Nordic Life Science Days in Malmö to meet with investors and pharma partners.

April 2017MonTa Biosciences recruits PhD, Esper Boel former SVP in Novo Nordisk and strategic adviosor in immunotherapy to its Board of Directors

March 2017MonTa Biosciences attends BioEurope Spring in Barcelona to have meetings with more than 10 of the top 20 pharma companies.  The major aim is to get feedback on our technology and learn more about interests from big pharma and explore potentials for future partnership.

  March 2017MonTa Biosciences closes an investment from Pre-Seed Innovation to reach key milestones for our cancer immunotherapy candidate. Read more here: Link

  September 2016MonTa Biosciences join the NOME Mentoring programme in the North Carolina Research Triangle and are appointed top professional mentors; The biotech entrepreneurs Sheila Mikhail and Rosina Pavia.

  August 2016 MonTa Biosciences awarded to be included in the NOME Nordic Mentoring Network for Entrepreneurship

MonTa Biosciences is priviledged to be part of the attractive Nordic Mentor Network for Entrepreneurship (NOME), which is an elite Nordic Mentoring program for promising life science ventures and world class mentors. 

In MonTa Biosciences we look forward to be mentored by some of the most talented CEOs and Life Science leaders in Denmark and the US, to learn from their experience, advice and network, in our attempt to create the strongest Company possible. 

   May 2016 - A news article was published by the Danish Biotech media; Medwatch on the newly granted XVac project. For more information go to the following link:

  April 2016 - MonTa Biosciences is part of the XVac "Grand Solutions"  granted as an Investment from "Innovationsfonden". The XVac project is a collaboration between DTU  Nanotech together with MonTa Biosciences and 3 other Companies.

  April 2016 - MonTa Biosciences Co-founder Thomas L Andresen talks in Danish national radio about the cancer immunotehrapy technology developed at DTU Nanotech that has been spun out to MonTa Biosciences. Hear the broadcast here:

  April 2015 - MedWatch publishes article on MonTa Biosciences.

 • March 2015 - The monocyte targeting technology was published in an article in  "Expert Opinion in Drug Delivery" 

 • September 2014 – MonTa Biosciences was awarded a "Proof-of-Concept" grant from Copenhagen Spin-puts" to support the early development of the company.  Copenhagen Spin-outs is a collaboration between the academic research environment and industry with a focus on innovation and commercialisation of biotech research in the capital region area.           

 
 

• August 2014 – MonTa Biosciences attracted a Pre-Seed Grant from Novo Seeds. Pre-Seed Grants support early-stage applied ground-breaking research that shows commercial potential. These grants are awarded on behalf of the Novo Nordisk Foundation and given to researchers at universities or medical staff at hospitals with the aim to mature a project for a seed investment. The Pre-Seed Grant allow us to expand our datapackage and demonstrate the strength of our technology further, meanwhile reducing risks of failures in the early development.

 (http://www.novo.dk/seeds/about)

 
• August 2014 – MonTa Biosciences establishes its office with access to research laboratories at DTU Nanotech. The benefit from having access to state-of-the-art research facilities is key for the early stages of development to enable fast progress with limited investment in space, laboratories and equipment.
 

• April 2014 - An article about MonTa Biosciences was published in Medwatch on April 8, 2014.

 
• November 2013: The MonTa Biosciences' technology was presented at the Society for Immunotherapy of Cancer "SITC" in National harbour, Washington DC, United States.